MCOLN1 and Duchenne muscular dystrophy: Although an in vivo efficacy of the synthetic agonists of TRPML1 has not been reported for any central nervous system (CNS) diseases, ML-SA compounds were shown to be muscle protective in a mouse model of DMD, a non-CNS disease (63, 243).